AR075516A1 - Composicion farmaceutica para inhalacion - Google Patents

Composicion farmaceutica para inhalacion

Info

Publication number
AR075516A1
AR075516A1 ARP100100474A ARP100100474A AR075516A1 AR 075516 A1 AR075516 A1 AR 075516A1 AR P100100474 A ARP100100474 A AR P100100474A AR P100100474 A ARP100100474 A AR P100100474A AR 075516 A1 AR075516 A1 AR 075516A1
Authority
AR
Argentina
Prior art keywords
inhalation
excipients
lactose
premixes
composition
Prior art date
Application number
ARP100100474A
Other languages
English (en)
Inventor
Yorick Kamlag
Morgane Lejeune
David Alexander Vodden
Original Assignee
Siegfried Generics Int Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siegfried Generics Int Ag filed Critical Siegfried Generics Int Ag
Publication of AR075516A1 publication Critical patent/AR075516A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composicion farmacéutica para inhalacion. Método para establecer las características de desempeno de dicha composicion y uso de dicha composicion en el tratamiento del asma, de la EPOC, de las alergias, de las enfermedades infecciosas y de las enfermedades del sistema cardiovascular. Reivindicacion 1: Un método para establecer las características de desempeno de una composicion farmacéutica para inhalacion, caracterizado porque comprende los siguientes pasos: a) proveer al menos dos premezclas, cada una de las cuales contiene una mezcla de un ingrediente con actividad farmacéutica y un excipiente apropiado; b) mezclar las al menos dos premezclas; y c) introducir la mezcla en un dispositivo de administracion apropiado, capaz de administrar la fraccion de medicamento en el sistema pulmonar de un paciente, donde la relacion de peso entre los excipientes de las al menos dos premezclas se fija entre 1 y 5. Reivindicacion 2: El método de la reivindicacion 1, caracterizado porque los excipientes usados en las distintas premezclas son iguales o diferentes. Reivindicacion 3: El método de la reivindicacion 2, caracterizado porque los excipientes son diferentes desde el punto de vista químico. Reivindicacion 4: El método de la reivindicacion 2 o 3, caracterizado porque el valor d50 de los excipientes individuales difiere más de 10%, preferiblemente más de 15%, más preferiblemente más de 20%. Reivindicacion 5: El método de una o más de las reivindicaciones precedentes, caracterizado porque los al menos dos ingredientes con actividad farmacéutica se seleccionan del grupo que consiste en ingredientes activos apropiados para la inhalacion, preferiblemente analgésicos, agentes anti-anginales, antialergénicos, antibioticos, antiinfecciosos, antihistamínicos, antiinflamatorios, antitusivos broncodilatadores, drogas anticolinérgicas, hormonas, xantinas, vacunas, proteínas o péptidos terapéuticos y combinaciones de éstos, más preferiblemente albuterol, beclometasona, budesonida, carmoterol, ciclesonida, fenoterol, fluticasona, formoterol, indacaterol, ipratropio, mometasona, salbutamol, salmeterol, tiotropio y sales o solvatos farmacéuticamente aceptables de éstos. Reivindicacion 6: El método de una o más de las reivindicaciones precedentes, caracterizado porque los excipientes se seleccionan del grupo que consiste en los azucares y los sacáridos preferiblemente la lactosa con grado de inhalacion, preferiblemente el a monohidrato de lactosa en forma de lactosa cristalina, lactosa triturada o lactosa micronizada.
ARP100100474A 2009-02-18 2010-02-18 Composicion farmaceutica para inhalacion AR075516A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09153082A EP2221048A1 (en) 2009-02-18 2009-02-18 Pharmaceutical composition for inhalation

Publications (1)

Publication Number Publication Date
AR075516A1 true AR075516A1 (es) 2011-04-06

Family

ID=40810348

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100100474A AR075516A1 (es) 2009-02-18 2010-02-18 Composicion farmaceutica para inhalacion

Country Status (29)

Country Link
US (1) US8840930B2 (es)
EP (2) EP2221048A1 (es)
JP (1) JP2012517987A (es)
KR (1) KR20110120283A (es)
CN (1) CN102325523B (es)
AR (1) AR075516A1 (es)
AU (1) AU2010215490B2 (es)
BR (1) BRPI1008598A2 (es)
CA (1) CA2749231C (es)
CY (1) CY1119216T1 (es)
DK (1) DK2398464T3 (es)
EA (1) EA021123B1 (es)
ES (1) ES2607210T3 (es)
HK (1) HK1160034A1 (es)
HR (1) HRP20170014T1 (es)
HU (1) HUE030618T2 (es)
IL (1) IL214036A (es)
LT (1) LT2398464T (es)
MX (1) MX341250B (es)
NZ (1) NZ594026A (es)
PL (1) PL2398464T3 (es)
PT (1) PT2398464T (es)
RS (1) RS55527B1 (es)
RU (1) RU2493833C2 (es)
SI (1) SI2398464T1 (es)
SM (1) SMT201700095B (es)
UA (1) UA102138C2 (es)
WO (1) WO2010094731A2 (es)
ZA (1) ZA201105532B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
BR112013008974A2 (pt) 2010-10-12 2023-12-19 Cipla Ltd Composição farmacêutica, processo para fabricar uma composição farmacêutica e uso de uma composição farmacêutica
CN102451173B (zh) * 2010-10-22 2015-02-18 山东新时代药业有限公司 噻托溴铵胶囊型吸入粉雾剂
TR201105367A2 (tr) * 2011-06-02 2012-12-21 Bi̇lgi̇ç Mahmut Akış özellikleri geliştirilmiş bir kuru toz formülasyonu.
TR201205852A2 (tr) * 2011-06-02 2012-12-21 Bi̇lgi̇ç Mahmut Geliştirilmiş yeni kuru toz formülasyonu.
US20150202321A1 (en) * 2012-08-14 2015-07-23 Newgen Biopharma Corp. Compositions comprising chitosan-drug conjugates and methods of making and using the same
CN103860525B (zh) * 2012-12-11 2016-04-06 天津药物研究院 一种含有效成分安立生坦的胶囊型吸入粉雾剂及其制备工艺
KR20160030086A (ko) * 2013-04-29 2016-03-16 사노피 에스에이 흡입식 약학적 조성물 및 그를 포함하는 흡입기 장치
EP2991625A1 (en) * 2013-04-29 2016-03-09 Sanofi SA Inhalable pharmaceutical compositions and the inhaler devices containing them
EP2815739B1 (en) * 2013-06-17 2019-08-28 Arven Ilac Sanayi Ve Ticaret A.S. Inhalation composition filling method
UA118861C2 (uk) 2013-12-06 2019-03-25 Оріон Корпорейшн Спосіб отримання сухих порошкових композицій для інгаляцій
CN103784449A (zh) * 2014-02-18 2014-05-14 青岛市城阳区人民医院 一种包含茚达特罗和噻托溴铵的药物组合产品
PT109030B (pt) * 2015-12-15 2019-09-25 Hovione Farmaciência, S.A. Preparação de partículas inaláveis de zafirlucaste
CN107095875B (zh) * 2016-02-23 2022-03-18 天津金耀集团有限公司 一种昔奈酸沙美特罗丙酸氟替卡松复方粉吸入剂组合物
CN108066329B (zh) * 2016-11-11 2021-11-16 江苏恒瑞医药股份有限公司 一种吸入用氟替卡松或其衍生物的微粒的制备方法
CN107823193B (zh) * 2017-11-16 2021-02-05 广州迈达康医药科技有限公司 一种阿地溴铵吸入型粉雾剂及其制备方法
PT3833964T (pt) 2018-08-07 2023-08-17 Norton Waterford Ltd Aplicação de espetroscopia de raman para o fabrico de pós de inalação
CA3189493A1 (en) 2020-08-14 2022-02-17 Brian Paul O'NEILL An inhalable formulation of fluticasone propionate and albuterol sulfate
WO2022146255A1 (en) * 2020-12-31 2022-07-07 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi A process for the preparation of dry powder compositions for inhalation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4140689B4 (de) * 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
ATE239447T1 (de) 1997-09-29 2003-05-15 Inhale Therapeutic Syst In verneblern verwendbare, stabilisierte zubereitungen
ITMI991582A1 (it) * 1999-07-16 2001-01-16 Chiesi Farma Spa Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala
DE19947235A1 (de) * 1999-09-30 2001-04-05 Asta Medica Ag Neue Kombination von Loteprednol und beta¶2¶-Adrenorezeptor-Agonisten
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
WO2003024396A2 (en) 2001-09-17 2003-03-27 Glaxo Group Limited Dry powder medicament formulations
EP1494652A1 (en) * 2002-04-12 2005-01-12 Campina Nederland Holding B.V. Excipient for use in dry powder inhalation preparations
GB2395900A (en) * 2002-12-04 2004-06-09 Elan Drug Delivery Ltd Therapeutic composition for respiratory delivery
US20040152720A1 (en) * 2002-12-20 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powdered medicaments containing a tiotropium salt and salmeterol xinafoate
JP5524442B2 (ja) * 2004-02-06 2014-06-18 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 呼吸器疾患の治療のための、抗コリン作用薬及びβ−模倣薬の新規併用薬
CN101175480A (zh) 2005-03-16 2008-05-07 伊兰制药国际有限公司 纳米微粒白三烯受体拮抗剂/皮质类固醇制剂
GB0714134D0 (en) * 2007-07-19 2007-08-29 Norton Healthcare Ltd Dry-powder medicament

Also Published As

Publication number Publication date
IL214036A0 (en) 2011-08-31
EP2221048A1 (en) 2010-08-25
PT2398464T (pt) 2017-01-20
AU2010215490A1 (en) 2011-08-04
RU2493833C2 (ru) 2013-09-27
UA102138C2 (uk) 2013-06-10
CA2749231C (en) 2016-09-13
US20120071449A1 (en) 2012-03-22
CN102325523B (zh) 2015-03-04
PL2398464T3 (pl) 2017-09-29
SMT201700095B (is) 2017-03-08
AU2010215490B2 (en) 2014-01-16
CY1119216T1 (el) 2018-02-14
HK1160034A1 (zh) 2012-08-10
JP2012517987A (ja) 2012-08-09
MX2011008659A (es) 2011-12-16
US8840930B2 (en) 2014-09-23
KR20110120283A (ko) 2011-11-03
EA021123B1 (ru) 2015-04-30
RS55527B1 (sr) 2017-05-31
BRPI1008598A2 (pt) 2016-03-15
CN102325523A (zh) 2012-01-18
ZA201105532B (en) 2012-04-25
ES2607210T3 (es) 2017-03-29
EP2398464A2 (en) 2011-12-28
SI2398464T1 (sl) 2017-05-31
NZ594026A (en) 2013-09-27
MX341250B (es) 2016-08-12
WO2010094731A3 (en) 2011-06-30
EP2398464B1 (en) 2016-11-02
HUE030618T2 (en) 2017-05-29
EA201190108A1 (ru) 2012-01-30
DK2398464T3 (en) 2017-02-06
IL214036A (en) 2015-08-31
HRP20170014T1 (hr) 2017-05-05
CA2749231A1 (en) 2010-08-26
LT2398464T (lt) 2017-03-10
WO2010094731A2 (en) 2010-08-26
RU2011133322A (ru) 2013-03-27

Similar Documents

Publication Publication Date Title
AR075516A1 (es) Composicion farmaceutica para inhalacion
ES2687751T3 (es) Tratamiento de enfermedades respiratorias
ES2270806T3 (es) Combinaciones de formoterol y de una sal de tiotropio.
AR101593A2 (es) Formulación superfina de formoterol
JP2012517987A5 (ja) 吸入用の医薬組成物のfpd特性を設定する方法
BRPI0508170A (pt) formulações farmacêuticas para inaladores de pó seco, que compreendem um ingrediente ativo de potência de baixa dosagem
AR067639A1 (es) Medicamentos pulverulentos que contienen tiotropio y salmetrol, asi como lactosa como excipiente
BR0308274A (pt) Formulação de formoterol superfino
FI3500241T3 (fi) Yhdistelmähoito copd:lle
ES2775606T3 (es) Furoato de fluticasona en el tratamiento de la EPOC
JP2013531056A5 (es)
FI2265257T4 (fi) Aklidiniumia käsittävä inhalaatiokoostumus kroonisen keuhkoahtaumataudin hoitamiseksi
CN103501781A (zh) 吡咯糖用于治疗心动过速的用途
NZ627837A (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
JP2019528316A5 (es)
JP2012522767A (ja) ステロイド性[3,2−c]ピラゾール誘導体および第二の薬学的活性化合物を含む医薬組成物
KR20170003601A (ko) Copd의 치료를 위한 티오트로피움 브로마이드, 포르모테롤 및 부데소니드의 조합
JP2015519356A5 (es)
AR040450A1 (es) Formulacion superfina de salmeterol
WO2005044187A3 (en) Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same
UY28589A1 (es) Nuevas sales de tiotropio, procedimientos para su preparación , así como formulaciones medicamentosas que las contienen
WO2005044186A3 (en) Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
Ahmadiafshar et al. Efficacy and safety of inhaled and intranasal corticosteroids
RU2020112519A (ru) Ингалятор и сетка для ингалятора
PAVIA et al. Preliminary data from phase II studies with Respimat, a propellant-free soft mist inhaler

Legal Events

Date Code Title Description
FB Suspension of granting procedure